SCHEMBL5149098

SCHEMBL5149098

CCn1nc(-c2nc(C(=O)O)c(NCc3ccc(OC)cc3)nc2-c2ccccc2)ccc1=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.43
MAPT P10636 3/20 0.43
POLB P06746 1/20 0.43
HDAC1 Q13547 1/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
TP53 P04637 1/20 0.42
RXFP1 Q9HBX9 1/20 0.42
HCRTR1 O43613 1/20 0.41
HCRTR2 O43614 1/20 0.41
KDM4E B2RXH2 3/20 0.41
ALDH1A1 P00352 3/20 0.41
HPGD P15428 2/20 0.41
NPSR1 Q6W5P4 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
KLKB1 P03952 2/20 0.40
KLK1 P06870 2/20 0.40
ACHE P22303 1/20 0.40
BACE1 P56817 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5149209 0.87 MAPT (0.45) HIF1ASMN1; SMN2MAPTPOLBMEN1
SCHEMBL5148007 0.87 MAPT (0.45) HIF1ASMN1; SMN2MAPTPOLBMEN1
SCHEMBL5149125 0.86 ALDH1A1 (0.46) HIF1ASMN1; SMN2MAPTPOLBHDAC1
SCHEMBL5147979 0.82 GAA (0.43) HIF1ASMN1; SMN2MAPTHDAC1MEN1
SCHEMBL5148003 0.77 HIF1A (0.46) HIF1AMAPTPOLBMEN1KMT2A
SCHEMBL5147975 0.75 ALDH1A1 (0.48) HIF1AMAPTPOLBMEN1KMT2A
SCHEMBL5147948 0.75 HIF1A (0.44) HIF1AMAPTPOLBMEN1KMT2A
SCHEMBL27679564 0.74 KDM4E (0.51) HIF1APOLBMEN1KMT2AKDM4E
SCHEMBL5149076 0.73 ALDH1A1 (0.46) HIF1AMAPTPOLBMEN1KMT2A
SCHEMBL5148912 0.73 ALDH1A1 (0.46) HIF1AMAPTPOLBMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7265120-B2 Pyrazine derivatives and pharmaceutical use thereof ASTELLAS PHARMA INC. (JP) 2007-09-04 US disclosed
CN-1938296-A Pyrazine derivatives and pharmaceutical use thereof as adenosine antagonists ASTELLAS PHARMA INC (JP) 2007-03-28 CN disclosed
US-20050222159-A1 Pyrazine derivatives and pharmaceutical use thereof FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2005-10-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050222159-A1 Pyrazine derivatives and pharmaceutical use thereof ADORA2A, HTR5A, ADORA1 HIF1A 416/4885SMN1; SMN2 1645/4885MAPT 1048/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.